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Abstract
Background: Lifestyle modification is fundamental to obesity treatment, but few studies have described the effects
of structured lifestyle programmes specifically in bariatric patients. We sought to describe changes in
anthropometric and metabolic characteristics in a cohort of bariatric patients after participation in a nurse-led,
structured lifestyle programme.
Methods: We conducted a retrospective, observational cohort study of adults with a body mass index (BMI) ≥40 kgm−2
(or ≥35 kgm−2 with significant co-morbidity) who were attending a regional bariatric service and who completed a single
centre, 8-week, nurse-led multidisciplinary lifestyle modification programme. Weight, height, waist circumference, blood
pressure, HbA1c, fasting glucose and lipid profiles as well as functional capacity (Incremental Shuttle Walk Test) and
questionnaire-based anxiety and depression scores before and after the programme were compared in per-protocol
analyses.
Results: Of 183 bariatric patients enrolled, 150 (81.9 %) completed the programme. Mean age of completers was 47.9
± 11.2 years. 34.7 % were male. There were statistically significant reductions in weight (129.6 ± 25.9 v 126.9 ± 26.1 kg,
p < 0.001), BMI (46.3 ± 8.3 v 44.9 ± 9.0 kgm−2, p < 0.001), waist circumference (133.0 ± 17.1 v 129.3 ± 17.5 cm in women
and 143.8 ± 19.0 v 135.1 ± 17.9 cm in men, both p < 0.001) as well as anxiety and depression scores, total- and
LDL-cholesterol and triglyceride levels, with an increase in functional capacity (5.9 ± 1.7 v 6.8 ± 2.1 metabolic
equivalents of thermogenesis (METS), p < 0.001) in completers at the end of the programme compared to the start.
Blood pressure improved, with reductions in systolic and diastolic blood pressure from 135 ± 16.2 to 131.6 ± 17.1
(p = 0.009) and 84.7 ± 10.2 to 81.4 ± 10.9 mmHg (p < 0.001), respectively. The proportion of patients achieving target
blood pressure increased from 50.3 to 59.3 % (p = 0.04). The proportion of patients with diabetes achieving
HbA1c <53 mmol/mol increased from 28.6 to 42.9 %, p = 0.02.
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Conclusions: Bariatric patients completing an 8 week, nurse-led structured lifestyle programme had improved
adiposity, fitness, lipid profiles, psychosocial health, blood pressure and glycaemia. Further assessment of this
programme in a pragmatic randomised controlled trial seems warranted.
Keywords: Bariatric, Structured lifestyle modification, Cardiovascular risk, CLANN (Changing Lifestyle with Activity and
Nutrition) Programme, Nurse-led, Diabetes
Background
Consistent with global trends, the prevalence of over-
weight and obesity has increased steadily in Ireland over
the past three decades [1, 2]. This is a public health
concern because of the associated morbidity and mortal-
ity from diseases like type 2 diabetes, for which the
population attributable risk from obesity is 50 to 80 %
[3, 4]. There is also a significant health economic burden
associated with obesity, which accounts for €1.1 billion
of public spending per annum in Ireland [5]. Public
health strategies to reduce calorie intake and increase
physical activity have not been successful to date. The
population shift in body mass index (BMI) has led to a
particularly dramatic rise in the prevalence of severe
obesity [6]. For these individuals (conventionally defined
as those with a BMI ≥40 kg m−2 or ≥35 kg m−2 with co-
morbidities such as type 2 diabetes), relatively intensive
“bariatric” interventions need to be adopted [7]. These
include intensive dietary restriction [8] and bariatric
surgery [9]. In a US cohort of bariatric surgical patients,
the prevalence of hypertension was 49 %, type 2 diabetes
was 28 % and dyslipidaemia was 46 % at baseline, which
was reduced or resolved by 68, 75 and 71 % respectively
after a mean post-surgical follow up of 34 months, with
a 40 % relative reduction in cardiovascular risk in that
time [10]. While bariatric surgical interventions are
efficacious and cost effective [11], they are also invasive,
expensive and unsuitable for a significant proportion of
bariatric patients.
Lifestyle modification is the cornerstone of the thera-
peutic approach to the obese patient. Several studies
have confirmed the benefits of structured lifestyle inter-
ventions in different patient subgroups, including those
with non-diabetic hyperglycaemia [12–14], prevalent
cardiovascular disease [15] or established type 2 diabetes
[16]. However, studies of such interventions in bariatric
patients are limited and often include meal replacement
regimes, which can be very effective in the short term
but are not designed to induce sustained dietary changes
and are associated with low retention rates [17]. In one
US study of 130 bariatric patients undergoing a twelve-
month diet and physical activity programme, weight loss
at 1 year was 11 kg, with significant reductions in waist
circumference, visceral and hepatic fat, blood pressure
and insulin resistance, with a study retention rate of
78 % [18]. However, there was still a meal replacement
component to this trial and to our knowledge, no
previous study has examined the effects of a multidiscip-
linary lifestyle modification programme that does not
include a prescribed diet or meal replacement regimen
in bariatric patients.
As part of the recent establishment of a regional
bariatric service in the West of Ireland, we have adopted
an 8 week structured lifestyle modification programme
known as the CLANN (Changing Lifestyle with Activity
and Nutrition) for patients with severe obesity. This
programme incorporates some key principles which have
already been associated with successful reduction in
anthropometric and metabolic cardiovascular risk factors
in adults with prevalent cardiovascular disease [19, 20].
Our objective in this study was to measure the effect of
this programme on relevant cardiovascular outcomes. In
achieving that objective, we hope to facilitate the more
robust design of a randomised controlled trial to deter-
mine the programme’s effectiveness in bariatric patients.
Methods
The study population included bariatric patients ≥18 years
old with a BMI ≥40 kg m−2 (or ≥35 with co-morbidity) who
were willing to attend a community-based facility where
the CLANN programme is delivered for 2 h per week for
8 weeks. Each patient was referred after careful assessment
for suitability by the hospital-based, multidisciplinary
bariatric team. Patients with poorly controlled diabetes or
hypertension, symptoms suggestive of untreated ischaemic
heart disease, an inability to walk 10 m or those deemed
unlikely to attend for the full programme (e.g. frequent
clinic non-attendance) were excluded from the programme.
The 8-week programme focused on weight management
as part of a comprehensive cardiovascular risk reduction
strategy. The main emphasis of the programme is on
lifestyle modification, namely healthy food choices, weight
reduction, physical activity and smoking cessation. We
based our definition of “healthy food choices” on the
European guidelines on healthy eating for cardiovascular
disease prevention [21]. Specifically, these stipulate
saturated fatty acids <10 % of total daily energy intake,
trans-unsaturated fatty acids <1 % of total daily energy
intake, salt consumption <5 g/ day, fibre intake 30–45 g/
day, fruit >200 g/ day (2–3 servings), vegetables >200 g/
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day (2–3 servings), fish at least twice per week, (one “oily”)
and alcohol consumption <20 g/ day for men and <10 g/
day for women. The Irish “Food Pyramid” (published by
the Irish Government’s Department of Health in 2012) was
used as a visual tool to encourage the adoption of these
dietary guidelines and to describe portion sizes to the
participants. We sought to encourage a cardioprotective
diet and to achieve an energy deficit of 600 kcal/ day, in
order to achieve a target weekly weight loss of 0.5 kg.
Initially, all patients received an individualised assess-
ment by the multidisciplinary team (nurse, dietitian,
physiotherapist, physical activity specialist). This included
recording use of cardioprotective medications such as
antihypertensive and antiplatelet agents and statins. The
assessment also sought to identify individual priorities and
needs and to explore beliefs, barriers and motivators to
change. Following this assessment, patients attended the
8-week programme, consisting of a group-based exercise
programme combined with educational workshops,
lasting 2 h each week. Effective exercise and physical activ-
ity strategies which were specific, measurable, achievable,
realistic and timed were also emphasised. These were
initiated in the programme without specialist gym
equipment with the objective of the patient maintaining
these behaviours in the longer term after completion of
the programme. While the exercise sessions were group-
based for maximum efficiency, each patient had an indivi-
dualised programme based on an assessment of their
needs by the physiotherapist and exercise physiologist.
The curriculum of eight theory-based health promotion
workshops incorporated a module on “understanding
cardiovascular disease”, two modules on “eating for a
healthy shape” (emphasising dietary modification tech-
niques such as carbohydrate counting, food label inter-
pretation and portion size calculation) and a module each
on “exercising for life”, “reading and understanding food
labels”, “stress management”, “dealing with the psycho-
logical issues of obesity” (including mindfulness) and
“maintaining a healthy lifestyle”.
Individualised goal setting occurred at the initial assess-
ment and then continued throughout the programme.
Motivational interviewing was used to support patients in
progressing through the stages of behaviour change, by
enhancing intrinsic motivation, autonomy and self-efficacy.
All patients were given a personal record card which they
were encouraged to use on a weekly basis to record their
goals and track their progress in relation to weight, BMI,
blood pressure, lipid profile and for patients with diabetes,
HbA1c and glucose levels.
At initial assessment, dietary habits, physical activity
levels (7-day physical activity recall), functional capacity
(Incremental Shuttle Walk Test [22], (ISWT) from
which a Heart Rate Walking Speed Index (HRWSI) was
derived) and psychosocial measures (questionnaire-based
anxiety and depression scores) were recorded. Specific-
ally, the Hospital Anxiety and Depression Scale (HADS)
[23], EQVAS (European Quality of Life Questionnaire,
Visual Analogue Scale) [24] and Dartmouth COOP [25]
questionnaires were administered. Weight was measured
using a Seca® 877 scale and height with a Seca® Leicester
stadiometer. Blood pressure was measured with an
Omron® 705IT oscillometric device in both arms after the
patient was sitting comfortably for five minutes. All of these
measures were repeated following completion of the
programme. The outcome targets were based on the 2012
European Society of Cardiology (ESC) prevention guide-
lines [21]. Specifically, the blood pressure target was 140/
90 mmHg (140/ 85 in patients with type 2 diabetes) while
the lipid targets were total cholesterol <5 mmol/l, LDL
cholesterol <3 mmol/l and triglycerides <1.7 mmol/l. The
study was approved by the Galway Clinical Research Ethics
Committee (the ethics committee for Galway University
Hospitals). Patients signed written informed consent for
their data to be used in the study.
Laboratory analysis
All blood samples were analysed locally in the Galway
University Hospitals’ Department of Clinical Biochemistry
(certified to ISO 15189 2007 accreditation standard).
HbA1c was measured with HPLC (Menarini® HA8160
auto-analyzer). Total cholesterol was measured using the
CHOP-PAP method. High density lipoprotein (HDL)-chol-
esterol and triglycerides were measured using the enzym-
atic and the GPO-PAP methods, respectively (Roche
COBAS® 8000 modular analyzer). Low density lipoprotein
(LDL)-Cholesterol was derived with the Friedewald equa-
tion [26].
Statistical analysis
Differences between outcomes at the start and the end of
the programme for patients who completed the programme
were assessed using the paired exact test for categorical
variables, the paired t-test for normally distributed continu-
ous variables and the Wilcoxon matched pairs test for non-
normally distributed continuous variables. All analyses were
performed using SPSS version 21.
Results
Of 183 patients enrolled, 150 (81.9 %) completed the
programme. Their baseline socio-demographic charac-
teristics are shown in Table 1. Mean age was 47.9 ±
11.3 years. 57 (31 %) had type 2 diabetes at baseline.
Overall, of 136 (92.7 %) of participants who provided
information about their employment status, 78 (57.4 %)
were unemployed. Most participants were “White Irish”,
though 51 (34 %) did not provide information about
their ethnicity. Similarly, 47 participants (31.3 %) did not
provide information about their educational background.
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The baseline and follow-up anthropometric and metabolic
characteristics of programme completers are presented in
Table 2. Patients who completed the programme had
statistically significant reductions in weight, BMI, waist
circumference and blood pressure. Changes in blood
pressure were greater in those who had suboptimal blood
pressure at baseline, defined as >140/85 and >140/
90 mmHg in patients with and without type 2 diabetes,
respectively [27]. The proportion of patients with blood
pressure readings at target increased from 50.3 % at
baseline to 59.3 % at follow-up, p = 0.04. There were
reductions also in self-reported depression and anxiety
levels and some, but not all components of the lipid profile.
HbA1c decreased slightly in the whole group, with greater
reductions in those with type 2 diabetes. The proportion of
patients with type 2 diabetes achieving optimal control
(HbA1c <53 mmol/mol or 7 %) increased from 28.6 % at
baseline to 42.9 % at follow-up, p = 0.02. The proportion of
patients achieving targets for moderate intensity aerobic
activity of 30 min five times per week [28] increased from
4.0 % at baseline to 38.4 % at follow-up, p < 0.001. There
were significant increases in various indices of aerobic
fitness and functional status, as shown in Table 1. Lastly,
changes in medication usage were minimised to the
greatest extent possible (Table 2). One patient stopped their
calcium channel blocker and one patient started an ACE
inhibitor, otherwise no changes were made to these
medications.
In order to determine whether the response to the
intervention was different for men and women, we used
regression modelling with the follow-up measure of the
variable of interest being the outcome and sex as the
exposure, adjusting for the baseline measure of that
variable. Overall, there were differential responses for
only a small number of outcomes. Specifically, men had
a greater reduction in waist circumference than women
(−3.4 [−6.0, −0.8] cm, p = 0.009). Men had statistically
significantly greater improvements in some but not all
indices of aerobic fitness. Their reduction in heart rate
walking speed index (HRWSI) was greater (−1.0 [−1.8,
−0.2], p = 0.02) and their increase in estimated MET
max was greater (0.6 [0.1, 1.0] METs, p = 0.02), though
changes in metres scored on ISWT and METs achieved
were not statistically significantly different by sex. After
adjusting for baseline values, triglycerides were 12 %
lower in men than in women at follow up (p = 0.02).
Conversely the reduction in systolic blood pressure was
lower for men than for women, such that the decrease
in women was 6.6 [1.8, 11.4] mmHg (p = 0.007) more
than for men.
We also sought to determine whether there were any
differences at baseline in patients who completed the
programme compared to those who dropped out and
did not attend for follow-up assessment. Compared to
non-completers, completers were older (47.9 ± 11.2
versus 40.7 ± 12.9 years, p = 0.003), were more likely to
be men (34.7 versus 10.3 %, p = 0.008) and were more
likely to have diabetes (35.8 versus 13.8 %, p = 0.03).
There were no differences in smoking, employment, eth-
nicity or educational status, nor were there differences
in anthropometric measures such as weight, BMI, waist
circumference or blood pressure. As anticipated given
the above differences, HbA1c was higher in completers
than non-completers at baseline (47.9 ± 15.5 versus 39.7
± 5.1 mmol/mol, p = 0.02) and HDL cholesterol was
lower (1.15 ± 0.28 versus 1.29 ± 0.38, p = 0.03), though
there was no difference in other components of the lipid
profile. Also, medication usage was higher at baseline in
completers, for statins (33.6 versus 11.1 %, p = 0.02),
antiplatelets (27.9 versus 3.6 %, p = 0.004), ACEI/ ARBs
(38.9 versus 15.4 %, p = 0.03) and calcium channel
blockers (22.5 versus 0 %, p = 0.03) but not for
betablockers (7.4 versus 17.5 %, p = 0.26). Completers
had less self-reported anxiety at baseline (7 [5, 11] versus
Table 1 Baseline socio-demographic characteristics of 150
severely obese adults completing the Croi CLANN programme
N Proportion (%)
Demographic variables
Female 98/ 150 65.3
Current smoker 18/ 150 12
Living with partner 91/ 144 60.7
Prevalent diabetes 53/ 148 35.8
Employment status (N = 136)
Employed full time 38 27.9
Employed part time 13 9.6
Self-employed full time 6 4.4
Self-employed part time 1 0.7
Retired 17 12.5
Unemployed 25 18.4
Looking after family 20 14.7
Student 9 6.6
Permanently sick 2 1.5
Temporarily sick 2 1.5
Other 3 2.2
Ethnicity (N = 99)
White / White Irish 98 99
Other ethnicity 1 1
Education level (N = 103)
Primary 23 22.3
Secondary 38 36.9
College / University 42 40.8
Proportions are expressed as a percentage of the total number of participants
for which data were available for that variable
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9 [6, 12], p = 0.04), though other psychometric measures
were not different. They achieved a shorter distance on
the incremental shuttle walk test (295 ± 130 versus 364
± 106, p = 0.01), though there were no differences in
other measures of fitness. We sought also to determine
whether the response to the programme was different
according to diabetes status. Compared to non-diabetic
patients, patients with diabetes who completed the
programme had a greater reduction in waist circumfer-
ence (−3.2 [−5.6, −0.7] cm, p = 0.01), though changes in
weight and BMI were not different. There was a trend to
a greater reduction in systolic blood pressure in those
without diabetes of 4.8 mmHg [0.0, 9.6], p = 0.05, but
not in diastolic blood pressure, lipid profile or any
measures of fitness. Changes in psychometric scores
were no different by diabetes status (data not shown).
Discussion
These findings confirm that a structured lifestyle modifica-
tion programme for carefully selected bariatric patients is
Table 2 Baseline and follow-up anthropometric and metabolic characteristics of 150 severely obese adults completing the Croi
CLANN programme
Variable N Baseline Follow-up Difference P-value
Mean ± SD Mean ± SD Mean 95 % Confidence Interval
Weight (kg) 150 129.6 ± 29.5 126.9 ± 26.1 −2.7 [−3.4, −2.0] <0.001
BMI (kg/m2) 150 46.3 ± 8.3 44.9 ± 9.0 −1.4 [−2.1, −0.7] <0.001
Waist (cm) - women 93 133.3 ± 17.1 129.3 ± 17.5 −3.7 [−4.9, −2.4] <0.001
Waist (cm) – men 50 143.8 ± 19.0 135.1 ± 17.9 −8.0 [−10.5, −5.4] <0.001
SBP (mmHg) 144 135.0 ± 16.2 131.6 ± 17.1 −3.3 [−5.8, −0.8] 0.009
DBP (mmHg) 144 84.7 ± 10.2 81.4 ± 10.9 −3.2 [−4.9, −1.6] <0.001
SBP (mmHg) a 71 145.5 ± 14.8 138.2 ± 17.3 −7.3 [−11.3, −3.3] <0.001
DBP (mmHg)a 71 91.7 ± 8.0 85.7 ± 11.3 −6.0 [−8.5, −3.5] <0.001
HbA1c (mmol/mol) 114 42 (37, 60) 41 (37, 53) 0 [−2, 0] 0.007
HbA1c (mmol/mol)b 51 61 (49, 71) 59 (45, 66) −3 [−5, 0] 0.006
Total Cholesterol (mmol/L) 145 4.7 ± 1.1 4.5 ± 1.0 −0.2 [−0.3, −0.1] 0.001
LDL Cholesterol (mmol/L) 138 2.7 ± 1.0 2.6 ± 0.9 −0.1 [−0.2, 0.0] 0.05
HDL Cholesterol (mmol/L) 145 1.2 ± 0.3 1.1 ± 0.3 −0.02 [−0.04, 0.01] 0.16
Triglycerides (mmol/L) 145 1.6 (1.1, 2.2) 1.4 (1.0, 1.9) −0.1 [−0.2, −0.01] <0.001
Total Cholesterol (mmol/L) c 62 5.8 ± 0.8 5.2 ± 0.9 −0.6 [−0.8, −0.4] <0.001
LDL Cholesterol (mmol/L) c 62 3.8 ± 0.8 3.4 ± 0.7 −0.4 [−0.6, −0.2] <0.001
Triglycerides (mmol/L)c 62 2.2 (1.9, 2.8) 1.9 (1.4, 2.8) −0.4 [−0.6, −0.03] <0.001
Metres scored on ISWT (m) 133 295 ± 130 350 ± 153 53 [41, 66] <0.001
METs achieved on ISWT (MET) 133 3.5 ± 0.9 3.8 ± 1.3 0.4 [0.3, 0.6] <0.001
Estimated MET max (MET) 133 5.9 ± 1.7 6.8 ± 2.1 0.9 [0.6, 1.1] <0.001
HRWSI 133 16.9 ± 4.3 15.5 ± 3.6 −1.4 [−1.9, −0.9] <0.001
Functional limitations score 83 20.5 ± 5.5 22.5 ± 5.3 2.0 [1.1, 2.9] <0.001
Anxiety score 110 7 (5, 11) 7 (4, 10) −1 [−2, 0] <0.001
Depression score 110 8 (5, 11) 4 (2, 7) −2 [−3, −1] <0.001
Dartmouth Coop score 110 26 ± 6 23 ± 7 −3 [−4, −2] <0.001
EQ-VAS 110 53 ± 22 60 ± 20 8 [4, 11] <0.001
Antiplatelet agents (%) 150 27.4 27.4 0 [−0.7, 0.7] 1.0
Statins (%) 150 34.3 34.3 0 [−0.7, 0.7] 1.0
ACEI/ ARB (%) 150 38.5 39.2 0.7 [−2.4, 3.8] 1.0
Betablockers (%) 150 17.6 17.6 0 [−0.7, 0.7] 1.0
Calcium channel blockers (%) 150 22.6 21.9 −0.7 [−2.7, 1.3] 1.0
Data are presented as mean ± standard deviation or as median (interquartile range)
aDenotes subgroup with elevated blood pressure at baseline assessment (>140/85 mmHg with diabetes or >140/90 with no diabetes)
bDenotes subgroup with prevalent type 2 diabetes at baseline
cDenotes subgroup not meeting that specific lipid subtype target at baseline [21]
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feasible and safe and leads to statistically significant
improvements in several cardiovascular risk-related
outcomes. The retention rate of 81.9 % compares
favourably with similar lifestyle intervention studies in this
patient group [17, 18]. While the overall effect size of the
programme in completers was relatively modest, the
reduction in BMI of 1.4 kgm−2 is identical to that seen in
cardiovascular patients attending the Croi “MyAction”
programme at the same facility [19]. We anticipated that
blood pressure and lipid profiles might not change to the
same extent in “Clann” as in “MyAction”, because we
sought to minimise any changes in medications during this
programme to the greatest extent possible, whereas in the
Croi “MyAction” programme the proportions of patients
on antiplatelets, renin-angiotensin related antihypertensives
and calcium channel blockers increased by 4.6, 4.9 and
5.6 %, respectively while the proportion on statins increased
from 40.3 to 65.1 %. The improvements we have observed
in the “Clann” programme have not arisen because of
increased prescribing of medications which lower
cardiovascular risk and are likely therefore to have been
driven by the programme itself.
The relatively small changes in body weight and BMI,
particularly in the context of the very abnormal level of
adiposity these patients have, might be seen as an
indicator that the overall impact on health of this
programme is not strong enough. While pervading
dogma suggests that any weight loss is good, recent
guidelines state that bariatric patients need to lose 15 %
or more of their body weight to have a meaningful
improvement in their health [29]. However, favourable
changes in body composition such as reduced fat mass
with concurrent increases in lean mass are unlikely to be
identified through changes in weight or BMI, so import-
ant and meaningful improvements may still have
occurred [30]. Moreover, fitness is a far more relevant
index of overall wellness and cardiovascular risk than
fatness [31, 32]. The mean increase of 15 % in aerobic
capacity (estimated MET max) of completers was a
strong indicator that the programme is in fact effective
and if sustained, might lead to a substantial reduction in
mortality [33, 34]. The improvements in depression
scores and components of the lipid profile are also
clearly relevant and important.
This study has a number of limitations. Firstly, it is a
retrospective, post-hoc cohort analysis without a pre-
specified primary outcome or a control group, so while
the findings provide a useful indication for effect size of
this programme on various outcomes, we cannot
determine its effectiveness. Out of necessity we have
only measured changes in outcomes in patients who
attended for follow-up assessments. These are likely to
represent a more motivated subgroup than non-
completers, which would lead to an overestimation of
the potential benefits of the intervention compared to
an analysis which included data from patients who did
not complete the intervention. Completers were older,
more likely to be male and have diabetes, were taking
more medications and may have been less fit, but we
don’t believe these differences with non-completers
account exclusively for the changes we have observed
after participation in the programme. It is difficult to
refine a target population for recruitment to the
programme on the basis of results reported herein, but
larger scale studies might help to identify patients who
are likely to remain in the intervention and benefit from
it. Notwithstanding the differences in the response to
the intervention for some outcomes by sex and diabetes
status, these weren’t strong or consistent enough to
suggest that the intervention should be limited to
specified subgroups of patients.
There may have been a Hawthorne effect, whereby
outcomes were different by virtue of the fact that they
were being measured twice [35]. For example patients
may have felt it polite to report that they were feeling
less depressed or may have made more of an effort on
their ISWT at the second attempt. However, objective
improvements in the HRWSI, several metabolic variables
and validated questionnaires are unlikely to be due
entirely to measurement effect, we believe. As these
patients were carefully selected for inclusion by a
hospital-based regional bariatric multidisciplinary team,
the results may not be generalisable to the broader
population of adults with severe obesity. For some
variables, there was a relatively high proportion of
missing data. For example, the functional limitations
score was measured before and after the programme in
only 55 % of completers, while 73 % completed
questionnaires and 76 % had HbA1c measured at both
visits. This may have introduced bias to the results. A
prospectively designed pragmatic randomised controlled
trial, with blinded assessment, would address many of
these limitations. The study has a number of strengths
in addition to the high patient retention rate. The
programme was delivered in a consistent way to all
patients by experienced staff. Adherence to a predefined
curriculum of teaching objectives during the health-
promotion workshops is likely to have enhanced the
integrity of the programme. Similarly, the assessments
were comprehensive and were completed according to
standardised protocols. Medication usage for hyperten-
sion, dyslipidaemia and diabetes was recorded carefully
at the start and end of the programme.
Conclusions
In a well-defined cohort of predominantly white adult
bariatric patients attending a regional obesity referral
centre who were identified as highly motivated and
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suitable for a nurse-led structured lifestyle modification
programme, the programme led to significant improve-
ments in anthropometric, metabolic and cardiovascular
risk variables over 10 weeks. Given that the programme
appears feasible, safe and acceptable to patients, with a
high retention rate and equivalent improvements to
similar interventions in other cohorts of high risk
individuals, future studies assessing the impact of
structured lifestyle modification in bariatric patients
could use it as a framework. The paucity of effective
therapeutic strategies apart from bariatric surgery and
meal replacement diets for these patients justify the
formal assessment of this programme in a randomised
controlled trial. Future studies might include more de-
tailed patient phenotyping to determine changes not just
in weight and BMI but in fat- and lean- mass and other in-
dices of body composition. Additionally, future studies
might examine proximal metabolic outcomes such as in-
sulin sensitivity which are linked to cardiovascular risk.
These studies will need to focus on more complete acqui-
sition of socio-demographic and functional limitation
questionnaire data.
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